基石药业-B(02616.HK)将携CS2015(OX40L/TSLP双特异性抗体)亮相ACAAI 2025
CSTONE PHARMACSTONE PHARMA(HK:02616) Ge Long Hui·2025-09-15 00:08

Core Viewpoint - Company announced that its pipeline asset CS2015, a dual-specific antibody targeting OX40L and TSLP, has been selected for presentation at the 2025 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting, scheduled for November 6-10 in Orlando, USA [1] Group 1: Product Development - CS2015 is a potential first-in-class/best-in-class dual-specific antibody that targets both OX40L and TSLP [1] - The antibody aims to provide new treatment strategies for type 2 inflammatory diseases such as atopic dermatitis (AD), asthma, and chronic obstructive pulmonary disease (COPD) by dual inhibition of key regulatory factors involved in Th2-mediated inflammatory responses [1]